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A B S T R A C T
Background
Resistance to triazoles was recently reported in Aspergillus fumigatus isolates cultured from 
patients with invasive aspergillosis. The prevalence of azole resistance in A. fumigatus is 
unknown. We investigated the prevalence and spread of azole resistance using our culture 
collection that contained A. fumigatus isolates collected between 1994 and 2007.
Methods and Findings
We investigated the prevalence of itraconazole (ITZ) resistance in 1,912 clinical A. fumigatus 
isolates collected from 1,219 patients in our University Medical Centre over a 14-y period. The 
spread of resistance was investigated by analyzing 147 A. fumigatus isolates from 101 patients, 
from 28 other medical centres in The Netherlands and 317 isolates from six other countries. The 
isolates were characterized using phenotypic and molecular methods. The electronic patient 
files were used to determine the underlying conditions of the patients and the presence of 
invasive aspergillosis. ITZ-resistant isolates were found in 32 of 1,219 patients. All cases were 
observed after 1999 with an annual prevalence of 1.7% to 6%. The ITZ-resistant isolates also 
showed elevated minimum inhibitory concentrations of voriconazole, ravuconazole, and 
posaconazole. A substitution of leucine 98 for histidine in the cyp51A gene, together with two 
copies of a 34-bp sequence in tandem in the gene promoter (TR/L98H), was found to be the 
dominant resistance mechanism. Microsatellite analysis indicated that the ITZ-resistant isolates 
were genetically distinct but clustered. The ITZ-sensitive isolates were not more likely to be 
responsible for invasive aspergillosis than the ITZ-resistant isolates. ITZ resistance was found in 
isolates from 13 patients (12.8%) from nine other medical centres in The Netherlands, of which 
69% harboured the TR/L98H substitution, and in six isolates originating from four other 
countries.
Conclusions
Azole resistance has emerged in A. fumigatus and might be more prevalent than currently 
acknowledged. The presence of a dominant resistance mechanism in clinical isolates suggests 
that isolates with this mechanism are spreading in our environment.
The Editors' Sum m ary o f  this article follows the references.
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Introduction
T he sap rophy tic  m ou ld  Aspergillus is know n to cause a 
spectrum  o f diseases in  hum ans includ ing  allergic syndrom es, 
noninvasive infections, as well as invasive aspergillosis. T he 
m orb id ity  and  m orta lity  associated  w ith invasive aspergillosis 
is high, a lthough  the m orta lity  ra te  appears to  be im proving  
partly  because o f th e  use o f effective an tifungal agents, m ost 
no tab ly  th e  triazo les [1]. V oriconazo le  was su p e r io r  to 
am p h o te ric in  B fo r the tre a tm e n t o f invasive aspergillosis 
and  has becom e th e  p rim ary  choice to  tre a t this co n d itio n  [2]. 
R ecently, a n o th e r triazole, posaconazole, was re p o r te d  to  be 
h igh ly  e ffec tive  in  p re v e n tin g  invasive asperg illosis  in  
n eu tro p aen ic  p a tien ts  w ith  acu te  m yeloid leukaem ia and  
m yelodysplastic syndrom e and  in  p a tien ts  w ith graft-versus- 
host-disease [3,4]. As a consequence, the ro le o f the  class o f 
azole com pounds will fu r th e r  increase in  the m anagem ent o f 
invasive aspergillosis.
We recen tly  observed the em ergence o f m ultip le-triazo le- 
resistance (MTR) in A. fumigatus, th e  p rim ary  cause o f invasive 
aspergillosis [5]. P atien ts w ith MTR aspergillosis p resen ted  
w ith p rim ary  invasive aspergillosis o r  w ith  b reak th ro u g h  
in fec tion  while receiv ing  itraconazo le  (ITZ) o r  voriconazole. 
T he p a tien ts  w ere fro m  six d if fe re n t hosp ita ls  in T he 
N etherlands, and  th e re  was no evidence fo r sp read  o f a 
single clone [5]. T he isolates w ere highly res is tan t to ITZ and  
show ed elevated  m in im um  inh ib ito ry  co n cen tra tio n s (MICs) 
o f voriconazole, posaconazole, and  the experim en ta l azole 
ravuconazole [5,6].
T he  em erg en ce  o f M TR in  A. fum igatus m ig h t have 
significant im pact on  the ro le o f azoles in  the m anagem ent 
o f invasive aspergillosis, b u t the im p ac t o f resistance on  the 
ro le o f azoles will greatly  d ep en d  on  th e  prevalence o f MTR 
and  th e  ability  to  d e tec t MTR isolates a t diagnosis [7]. 
H owever, th e  p revalence o f MTR is cu rren tly  unknow n, 
a lthough  th e  n u m b er o f p a tien ts  w ith a M TR isolate was 
fo u n d  to  be  sign ifican tly  h ig h e r  th a n  in  a p rev iously  
co n duc ted  surveillance study in  T he N etherlands [5,8]. We 
investigated  the prevalence o f azole resistance in  A. fumigatus 
in  a prospectively  collected  fungus cu ltu re  co llection  over a 
p e rio d  o f 14 y. We also investigated  th e  sp read  o f resistance 
by analysing isolates in  o u r  collection , ob ta in ed  from  o th e r 
hospitals in  T he N etherlands an d  o th e r countries.
Methods
Setting and Strain Selection
T he R adboud  U niversity  N ijm egen M edical C en tre  is a 
te rtia ry  care  hosp ita l w ith beds fo r 950 patien ts . T he m edical 
m icrobiology labo ra to ry  receives specim ens from  patien ts 
ad m itted  to  the hosp ita l as well as those seen as ou tpatien ts. 
T he mycology u n it o f th e  labo ra to ry  has th e  policy to 
rou tine ly  s to re  fungal isolates from  p a tien ts  w ith  fungal 
diseases ad m itted  to  the hosp ita l o r  seen as ou tpa tien ts. F o r 
Aspergillus species every isolate, irrespective  o f its clinical 
significance, was stored . In  add ition , fungi th a t w ere cu ltu red  
from  th e  hosp ita l en v iro n m en t o r  those sen t to  the  labo ra to ry  
fo r iden tifica tion , in  v itro  susceptib ility  testing  o r  as p a r t  o f 
research  co llabora tion , w ere stored . F rom  th e  isolates a spore 
suspension was m ade in  glycerol 10% and  s to red  a t —80 °C.
T he fungus cu ltu re  co llection  was searched  fo r A. fumigatus 
isolates. To investigate th e  p revalence o f azole resistance we
used  the  A. fumigatus isolates th a t w ere cu ltu red  from  patien ts 
th a t h ad  b een  ad m itted  to  o u r  hosp ita l o r  w ere seen as 
ou tpa tien ts. T he sp read  o f azole resistance was investigated  
by analysing isolates th a t had  b een  cu ltu red  a t o th e r  hospitals 
in T he N etherlands an d  sen t to  o u r labo ra to ry  fo r id e n ti­
fication. T he isolates in  o u r co llection  ob ta in ed  from  o th e r 
coun tries w ere also sc reened  fo r azole resistance.
All A. fum igatus iso lates w ere o rig inally  id en tif ied  by 
ex perienced  technicians on  th e  basis o f m acroscopic colony 
m orphology, m icroscopic m orphology  o f con id ia  and  con- 
id ia-fo rm ing  structu res, an d  the ability  to  grow a t 48 °C. The 
selected  A. fumigatus isolates w ere cu ltu red  on  Sabouraud  
slants fo r 7 d  an d  subsequently  su b cu ltu red  on  S abouraud  
slants su p p lem en ted  w ith itraconazole  a t a co n cen tra tio n  o f 8 
mg/l, and  in cu b a ted  a t 35 °C.
Phenotypic Analyses
F o r pheno typ ic  com parisons, fo r every p a tie n t from  o u r 
hosp ita l w ith an A. fumigatus isolate th a t grew  in th e  p resence 
o f 8 mg/l o f itraconazo le  (ITZ+), two co n tro l p a tien ts  w ere 
random ly  selected  w ith an  isolate th a t failed  to  grow  on  the 
itraconazo le  co n ta in in g  slants (ITZ—): one  in  th e  4 wk 
p reced ing  the ITZ+ A. fumigatus cu ltu re  da te  an d  one in  the
4 wk a fte r  th e  cu ltu re  date. In  add ition , one  co n tro l p a tien t 
was random ly  selected  fo r every rem ain ing  m o n th  fo r each 
year in  w hich a p a tie n t w ith an ITZ+ isolate was identified.
All IT Z + an d  ITZ— A. fumigatus co n tro l isolates w ere 
in v es tig a ted  fo r  th e i r  a n tifu n g a l su scep tib ility  o f ITZ, 
voriconazole, ravuconazole, posaconazole, am p h o te ric in  B, 
te rb inafine , an d  caspofungin  using  the CLSI M38-A b ro th  
m icro -d ilu tion  re fe rence  m eth o d  [9].
Genotypic Analyses
F o r genotypic com parisons, isolates w ere random ly  se­
lec ted  from  th e  ITZ— co n tro l p a tien ts  in  a 1:1 ra tio  w ith the 
ITZ+ patien ts . F o r ITZ+ an d  ITZ— isolates the full cod ing  
sequence o f b o th  strands o f the  cyp51A gene was d e te rm in ed  
by PCR am plification  and  analysed to  d e tec t m uta tions [6,10]. 
M olecular iden tifica tion  was p e rfo rm ed  by sequencing  of 
parts  o f th e  highly conserved b-tubu lin  and  calm odulin  gene, 
as described  previously [11-13], in  o rd e r  to  ru le  o u t any 
species w ith in  th e  Aspergillus section  Fumigati, w hich are 
closely re la ted  to  A. fumigatus, b u t are  d ifficult to  d iscrim inate  
based  on  m orphological fea tu res alone [12]. T he neighbour- 
jo in in g  (NJ) m eth o d  was used  fo r phylogenetic analysis. 
Sequences w ere com pared  w ith  those o f A. fumigatus, A. 
lentulus, A. viridinutans, A. brevipes, A. novofumigatus, A. 
fumigatiaffinis, and  Neosartorya species all ob ta in ed  from  the 
CBS Fungal B iodiversity C en tre , U trech t, T he N etherlands 
[14].
M icro sa te llite  g en o ty p in g  was u sed  to  d e te rm in e  the 
genetic  d istances betw een  the ITZ+ and  ITZ— A. fumigatus 
isolates and  analysed, as described  previously [15,16]. Allele 
sharing  d istance m atrices w ere g en era ted  [17], an d  these 
m atrices w ere used  as in p u t to  the N eighbor p ro g ram  o f the 
PHYLIP softw are package to  p ro d u ce  th e  dendrogram s [18].
Patient Characteristics
T he e lec tron ic  p a tie n t files w ere searched  fo r clinical 
in fo rm atio n  on  the p a tien ts  w ith an IT Z -resistan t A. fumigatus 
isolate and  from  the  contro ls. In fo rm atio n  collected  inc luded  
the  sam ple from  w hich th e  A. fumigatus isolate was cu ltu red ,
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Figure 1. Epidemiology of ITZ Resistance in the A. fumigatus Isolates
Blue bars represent the number of patients with a positive A. fumigatus culture (left y-axis) and the red line represents the percentage of those patients
with an ITZ+ isolate (right y-axis). The x-axis is the year.
doi:10.1371/journal.pmed.0050219.g001
the  underly ing  co n d itio n  o f th e  patien ts , and  the  p resence  o f 
invasive aspergillosis. Invasive aspergillosis was classified 
accord ing  to  the  E u ropean  O rgan iza tion  fo r R esearch and  
T rea tm en t o f C ancer and  Mycoses Study G roup  (EORTC)/ 
MSG consensus defin itions [19]. H um an  ex p erim en ta tio n  
g u idelines fro m  th e  C om m ittee  o n  R esearch  Involving 
H um an  Subjects A rnhem -N ijm egen  w ere follow ed in  the 
conduc t o f this research.
Statistical Analysis
To test w hether ITZ+ isolates h ad  b een  p re sen t th ro u g h o u t 
th e  o b se rv a tio n  p e r io d  (1994-2007), we ca lc u la ted  th e  
p robab ility  th a t th e  onset da te  o f find ing  an  ITZ+ was as 
la te  as we fo u n d  it to  be. F o r the pheno typ ic  analysis we used 
t-tests on  th e  n a tu ra l logarithm  o f the MIC’s and  fo r the 
genotypic analysis we used a C hi2 test. F o r th e  p a tie n t 
characteristics, the exact Chi2 test was used because o f th e  low 
expected  num bers in  certa in  cells.
Results
Prevalence of ITZ+ A. fum igatus Isolates
T he fungal cu ltu re  collection  inc luded  12,645 isolates th a t 
had  been  collected  betw een  1994 an d  2007. O f these, 2,683 
w ere iden tified  as A. fumigatus, and  1,912 w ere cu ltu red  from  
patien ts ad m itted  to  o u r  hosp ita l o r  seen as ou tpatien ts. 
T hese isolates w ere cu ltu red  from  1,219 patien ts , w ith a 
m ed ian  n u m b er o f p a tien ts  o f 92.5 p e r  year (range 48 to  138), 
w hich co rresp o n d ed  w ith a m ed ian  o f 130 A. fumigatus isolates 
p e r  year (range 72 to  215). All isolates w ere revived and  
subcu ltu red  on  S abou raud  slants co n ta in in g  8 mg/l o f ITZ at 
35 °C and  1,871 isolates fa iled  to  grow u n d e r  these conditions. 
H owever, 41 isolates from  32 patien ts w ere able to  grow on 
the IT Z -con ta in ing  agar. A n ITZ+ A. fumigatus isolate was 
c u ltu re d  fo r  th e  firs t tim e on  Ju n e  15, 2000. All 674 
consecutive clinical isolates from  462 pa tien ts cu ltu red  in  
the 6.5 y befo re  this da te  d id  n o t grow on  the IT Z -contain ing
S abou raud  agar. F rom  2000 onw ards, p a tien ts  w ere observed 
every year w ith an ITZ+ A. fumigatus isolate, w ith a m axim um  
prevalence o f 6.0%. U n d er th e  assum ption  o f a random  
d is trib u tio n  o f all ITZ+ isolates over the com plete  set o f n 
o b serv a tio n s , th e  p ro b a b ility  o f  f in d in g  th e  firs t o f  k 
occurrences a t observation  n u m b er o o r  la te r  is equal to  (n 
— o +  1) over k d iv ided by n over k. F o r th e  observations at 
h an d  this p robab ility  is so small (p <  0.001), th a t we can 
conclude th a t the ITZ+ isolates are  n o t random ly  d is trib u ted  
over all observations: ITZ+ isolates s ta rted  to  occu r a fte r a 
given tim e p o in t notab ly  a fte r  1994, b u t befo re  o r  equal to  
Ju n e  15, 2000 (Figure 1).
Phenotypic Analysis
F o r pheno typ ic  com parisons, th e  first ITZ+ isolate o f each 
o f the  32 iden tified  patien ts , was com pared  w ith those o f the 
co n tro l g roup . T he co n tro l g ro u p  consisted  o f 115 patien ts 
w ith one ITZ— A. fumigatus isolate p e r  pa tien t, rep resen tin g  at 
least one p a tie n t and  isolate from  every ca len d ar m on th  
b etw een  Ja n u a ry  1, 2000 an d  D ecem ber 31, 2007. The 
pheno types o f the 32 ITZ+ isolates and  the 115 ITZ— con tro l 
isolates fo r the azole com pounds are  show n in F igure 2. All 
ITZ+ isolates also show ed reduced  susceptib ility  to  v o ricona­
zole, ravuconazole, and  posaconazole in  com parison  w ith the 
ITZ— con tro ls (t-test, p <  0.0005). No significant d ifferences 
w ere o bserved  fo r  a m p h o te r ic in  B (t-test, p — 0.892), 
te rb inafine  (t-test, p — 0.591), and  caspofungin  (t-test, p — 
0.816) (unpublished  data).
Genotypic Analysis
F o r genotypic com parisons the first ITZ+ A. fumigatus 
isolate from  32 patien ts was com pared  w ith those o f 32 
random ly  selected  co n tro l patien ts. T he d o m in an t genetic 
changes in  th e  ITZ+ isolates in  th e  cyp51A gene w ere a p o in t 
m u ta tio n  a t t364a, lead ing  to  th e  su bstitu tion  o f leucine 98 
fo r h istid ine, to g e th e r w ith th e  p resence  o f two copies o f a 34- 
base p a ir  sequence in tandem  in th e  p ro m o te r  o f cyp51A gene
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Figure 2. Distribution of Proportions of MICs of 32 ITZ+ A. fumigatus Isolates (Blue Bars) and 115 ITZ— Controls (Red Bars) of ITZ (left upper panel), 
Voriconazole (right upper panel), Ravuconazole (left lower panel), and Posaconazole (right lower panel)
Left x-axis represents the proportion of isolates and on the right x-axis the MIC distribution is shown. 
doi:10.1371/journal.pmed.0050219.g002
(TR/L98H), as previously fo u n d  [5]. These changes w ere 
p resen t in  30 o f 32 (94%) ITZ+ isolates an d  these isolates 
exh ib ited  th e  previously re p o r te d  MTR phenotype. In  one 
ITZ+ isolate an  a729g change was fo u n d  to  be responsib le  fo r 
th e  su b s titu tio n  a t codon  220 o f m e th io n in e  by valine 
(M220V) and  in th e  o th e r  no m u ta tions in  th e  cyp51A gene 
w ere found . In  all 32 A. fumigatus ITZ— co n tro l isolates, the 
TR/L98H changes w ere n o t observed. To tes t th e  re la tion  
betw een an  ITZ res is tan t p h eno type  and  th e  p resence  o f TR/ 
L98H  a Chi2 test was perfo rm ed , and  th e re  was a significant 
re la tion  betw een  th e  two factors (v,2 — 50.143, d f — 1, p <  
0.0001). N o changes w ere fo u n d  in  the  cyp51A gene o f con tro l 
isolates, excep t fo r th ree  isolates, w ith  m uta tions th a t w ere 
n o t associated  w ith a res is tan t phenotype.
T he 64 ITZ+ an d  ITZ— isolates cou ld  be classified as A. 
fumigatus based on  sequence analysis o f parts  o f the b -tubulin  
and  calm odulin  genes. T h ree  clades w ere fo rm ed  based on 
the n e ig h bou r-jo in ing  (NJ) analysis o f the m icrosate llite  
typing; th e  ITZ+ isolates w ere genetically  d iffe ren t b u t 
c lustered  to g e th e r in  a single clade (Figure 3). F ou r ITZ+ 
isolates w ere c lustered  w ith in  the  ITZ— clades, two w ith the 
TR/L98H su bstitu tion  and  th e  o thers w ith  o th e r  o r  unknow n 
m utations. T he branches o f the ITZ+ isolates had  sh o rte r  
genetic d istances th an  those w ith in  the ITZ— isolate clades.
Patient Characteristics
In  17 o f 32 patien ts (53%), the ITZ+ isolate was cu ltu red  
from  a resp ira to ry  specim en  (ten spu tum  specim ens, fo u r 
b ronchoa lveo la r lavage fluids, an d  th ree  b ronch ia l secre­
tions), w hich was n o t significantly d iffe ren t to  78 o f 115 
p a tie n ts  (68% ) w ith  an  IT Z — iso la te  (41 sp u tu m , 22 
b ronchoa lveo la r lavage fluids, and  15 b ronch ia l secretions). 
A wide variety  o f underly ing  diseases an d  cond itions w ere 
p re sen t (Table 1), m ost notab ly  p a tien ts  w ith ch ron ic  lung 
diseases o r  cancer. Invasive aspergillosis was d iagnosed  in 
n ine  o f 32 p a tien ts  (28.1%) w ith an  ITZ+ isolate (three 
proven , th ree  p robab le , an d  th ree  possible cases) com pared  
to 25 o f 115 (21.7%) in  the  co n tro l g ro u p  (seven proven , 12 
p robab le, and  six possible cases), w hich was n o t significantly 
d ifferen t. T he characteristics o f the n ine  cases w ith  an  ITZ+ 
isolate are  show n in T able 2.
Spread of Azole Resistance
O u r cu ltu re  co llection  co n ta in ed  149 A. fumigatus isolates 
from  28 o th e r  hospitals from  20 d iffe ren t cities in  The 
N etherlands. These isolates h ad  been  cu ltu red  from  101 
p a tien ts  w ith aspergillus disease an d  had  been  sen t to  o u r 
labo ra to ry  betw een 1994 an d  2006. O f these, 22 (14.5%) 
isolates grew  on  the IT Z -con ta in ing  S abou raud  slants. The 
ITZ+ isolates h ad  been  cu ltu red  from  13 p a tien ts  (12.8%)
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Figure 3. Genotypic Relatedness of 32 ITZ+ A. fumigatus Isolates and 32 ITZ— Controls
The numbers are the identification numbers of the individual isolates. The ITZ+ A. fumigatus with the L98H substitution and a tandem repeat in the 
promoter region of the cyp51A gene are underlined and printed in red. The ITZ+ isolates with other or unknown resistance mechanisms are underlined 
and printed in blue. The ITZ— isolates are printed in black. 
doi:10.1371/journal.pmed.0050219.g003
from  n ine  d iffe ren t hosp itals from  seven cities in  The 
N etherlands (Table 3). T he first res is tan t isolate was cu ltu red  
in  1998, an d  all o thers a fte r  2000. T he TR/L98H changes w ere 
p resen t in  n ine  o f 13 (69%) ITZ+ isolates (Table 3).
O u r cu ltu re  co llection  co n ta in ed  317 A. fumigatus isolates 
from  six E u ropean  countries: Belgium, F rance, U n ited  K ing­
dom , Sweden, Norway, an d  Greece. These isolates had  been  
c u ltu re d  b e tw een  1994 a n d  2002 as p a r t  o f  re sea rch  
collaborations. Six isolates w ere res is tan t to  itraconazole, 
o rig ina ting  from  France, Sweden, Norway, and  th e  U n ited  
K ingdom , som e o f w hich have been  re p o r te d  previously 
(Table 3) [6,20-22]. T he isolate ob ta in ed  from  th e  U n ited  
K ingdom  was originally  cu ltu red  from  a p a tie n t in the U n ited
States in  1989 [22]. All azo le-resistan t isolates from  this g roup  
w ere cu ltu red  befo re  2000, excep t fo r th e  isolate from  
N orway, w hich was th e  only isolate w ith TR/L98H (Table 3).
Discussion
E m ergence o f azole resistance was observed in  all th ree  sets 
o f A. fumigatus isolates. Besides o u r  hosp ita l, azole-resistant 
isolates w ere fo u n d  in  n ine  o th e r  hospitals in  T he N e th e r­
lands, an d  in  fo u r  o th e r  co u n tr ie s . T he  p ro sp ec tiv e ly  
collected  isolates from  o u r hosp ita l in d ica ted  th a t resistance 
h ad  em erged  since 2000 w ith a prevalence betw een  1.7% and  
6% . T h e re fo re , azole re s is tan ce  in  A. fum igatus  is n o t
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Table 1. Classification of the Underlying Conditions in 32 Patients with an ITZ+ A. fum igatus  Isolate and 115 ITZ— Controls
Specialty Underlying Conditions Patients with Underlying Conditions Patients with
ITZ+ Isolate (% ) ITZ— Isolate (%)
Haematology MDS, AML (2), ALL, CML, MM, non-Hodgkin 8 (25) MDS (7), AML (6), ALL, CML (2), CLL (3), MM (3), 31 (26.9)
lymphoma, CLL Hodgkin lymphoma, myelofibrosis, non-Hodgkin
lymphoma (4), Waldenstrom disease, aplastic anaemia, 
mantel cell lymphoma
Lung diseases Cystic fibrosis (3), COPD (2) 5 (15.6) Cystic fibrosis (15), COPD (5), pneumonia, pulmonary 27 (23.4)
fibrosis, asthma (2), bronchiectasis (3)
Oncology Rhabdomyosarcoma, prostate cancer, 5 (15.6) Melanoma, bladder cancer, breast cancer (3), lung 11 (9.5)
thyroid cancer, oropharynx cancer, cancer (3), Bowen disease, oropharynx cancer, skin cancer
germinoma
Cardiology Aumaurosis fugax, atherosclerosis, angina 4 (12.5) Coronary artery bypass (4), aneurysma, atherosclerosis (2) 7 (6.0)
pectoris, coronary artery bypass
Surgery Pancreatitis 1 (3.1) Trauma (2), bladder surgery, pancreatitis, fracture (2), 9 (7.8)
Hernia cicatricialis, vascular, abdominal
Other Psoriasis, drug abuse, none 3 (9.4) Unknown (7), otitis externa (2), sinusitis, galactosaemia, 17 (14.8)
excema, Wegener disease, Down syndrome, CDG 
syndrome, systemic lupus erythematosus, keratitis
The number of patients is given in parentheses in ‘‘Underlying Conditions”  columns if >1.
Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphoblastic leukaemia; CML, chronic myeloid leukaemia; COPD, chronic obstructive
pulmonary disease; MDS, myelodysplastic syndrome; MM, multiple myeloma.
doi:10.1371/journal.pmed.0050219.t001
Table 2. Clinical Characteristics of Nine Patients with Invasive Aspergillosis and an Azole-Resistant A. fum igatus  Isolate
Classification9 Underlying Disease Date of 
Isolation
Treatment Outcome at 
Day 90
Comments
Proven Chronic granulomatous disease November 1, 2005 Caspofungin,
posaconazole
Survived Isolate was cultured at diagnosis. The patient was 
on itraconazole prophylaxis for over 10 y [5].
Proven Oropharynx carcinoma August 18, 2006 Voriconazole Died The patient had been infected with an azole 
susceptible and MTR isolate. The MTR isolate was 
first cultured at autopsy [7].
Proven Drug abuse July 17, 2007 Caspofungin and 
lobectomy
Survived The patient was previously treated with voriconazole.
Probable Kidney transplantation August 22, 2000 Amphotericin B, 
itraconazole
Survived The susceptibility of the culture was not known 
at the time the infection was treated.
Probable Chronic granulomatous disease April 4, 2002 Voriconazole Survived The infection developed while on itraconazole 
prophylaxis and the patient was treated with high 
doses of voriconazole [35].
Probable Non-Hodgkin lymphoma, alloHSCT (VUD) May 19, 2007 Voriconazole Survived The isolate was cultured from a sputum sample 
obtained during voriconazole therapy.
Possible Rhabdomyosarcoma May 12, 2004 Voriconazole Survived The susceptibility of the culture was not known 
at the time the infection was treated.
Possible Acute myeloid leukaemia, alloHSCT August 9, 2006 Caspofungin, 
amphotericin B
Died The isolate was cultured during treatment of 
invasive aspergillosis. The patient also developed 
invasive scedosporiosis and zygomycosis, proven at 
autopsy.
Possible Multiple myeloma, autoHSCT January 8, 2007 Itraconazole Survived The resistant isolate was cultured from a mouth 
wash sample. PET-CT scan showed pulmonary 
lesions consistent with invasive aspergillosis.
aAccording to the European Organization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions [19].
Abbreviations: AlloHSCT, allogeneic hematopoietic stem cell transplantation; autoHSCT, autologous hematopoietic stem cell transplantation; VUD, voluntary unrelated donor. 
doi:10.1371/journal.pmed.0050219.t002
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Table 3. Characteristics of Clinical A. fum igatus  Isolates Present in the Fungus Culture Collection Cultured from Other Hospitals in The 
Netherlands and from Other Countries
Isolate Identification Country City or Year of MIC Cyp51A Substitutions15
Number Region“ Isolation |TZ vcz  pCZ AMT TER CAS TR Codon 98 Other
V12-47 US California [22] 1989 >16 1 0.5 2 0.125 0.25 — — —
3038 France Paris 1995 >16 2 2 1 0.125 0.5 — — M220R
7720 Sweden Stockholm [20] 1997 16 1 0.5 0.5 0.125 0.125 — — —
7722 Sweden Stockholm [20] 1997 >16 0.25 0.5 0.5 0.031 0.25 — — —
8327 Sweden Stockholm [20] 1998 >16 1 0.5 0.5 0.5 0.25 — — M220I
V01-70 Norway Oslo [21] 2001 >16 8 0.5 0.5 0.125 0.125 + L98H —
V09-18 The Netherlands Groningen 1998 >16 1 0.5 0.5 0.063 0.25 + L98H S297T, F495I
V06-31 The Netherlands Nijmegen 2001 >16 2 0.5 0.5 0.063 0.25 + L98H —
V21-3 The Netherlands Groningen 2003 >16 2 0.5 0.5 0.125 0.25 + L98H S297T
V28-77 The Netherlands Leeuwarden 2004 >16 0.5 0.5 1 0.063 1 — — M220I
V34-75 The Netherlands Utrecht 2004 >16 4 0.25 0.5 0.125 0.125 + L98H —
V35-75 The Netherlands Nijmegen 2004 >16 2 0.5 0.5 0.063 0.25 — — —
V37-07 The Netherlands Utrecht 2005 >16 2 0.5 0.5 0.031 0.125 + L98H —
V41-26 The Netherlands Zwolle 2005 >16 16 1 2 0.5 0.125 + L98H —
V41-27 The Netherlands Zwolle 2005 8 0.5 0.125 2 0.25 0.125 — — —
V48-27 The Netherlands Rotterdam 2006 >16 8 0.5 0.5 0.031 0.125 + L98H —
V49-09 The Netherlands Zwolle 2006 >16 8 0.5 0.5 0.031 0.25 + L98H —
V49-29 The Netherlands Amsterdam [36] 2006 >16 16 0.25 1 0.125 0.5 ++ — —
V49-77 The Netherlands Leeuwarden 2006 >16 8 0.5 1 0.125 1 + L98H —
aNijmegen refers to hospitals other than the Radboud University Nijmegen Medical Centre. 
bTR, tandem repeat; TR+, 34-bp tandem repeat; TR++, 53-bp tandem repeat.
Abbreviations: AMT, amphotericin B; CAS, caspofungin; PCZ, posaconazole; TER, terbinafine; VCZ, voriconazole. 
doi:10.1371/journal.pmed.0050219.t003
uncom m on  an d  probab ly  m ore  w idespread  than  cu rren tly  
acknow ledged.
Recently, taxonom ic  changes have b een  p ro p o sed  fo r 
Aspergillus section  Fumigati, w ith  the d escrip tion  o f several 
new species th a t a re  closely re la ted  to  A. fumigatus [12]. Since 
som e o f these new species ap p e a r  to  be m ore  res is tan t to 
an tifungal com pounds th an  A. fumigatus [23], and  species 
dem arca tio n  by m orpho log ic  fea tu res alone is n o t reliably 
possible [24], we took  g rea t care to  co rrectly  identify  the 
species. O n  the basis o f sequence-based  analysis, we can be 
confiden t th a t th e  observed azole resistance has em erged  in  A. 
fumigatus.
A cqu ired  resistance against azoles develops in  response  to 
exposure o f fungi to  azole com pounds. Azole resistance has 
b een  show n to  develop follow ing exposure in  the p a tie n t and  
in  ag ricu ltu ra l settings [25-28]. Favourable cond itions fo r the 
developm ent o f azole resistance include long  d u ra tio n  o f 
d rug  exposure and  h igh num bers o f rep ro d u c in g  m icro ­
organism s [29]. In  patien ts w ith aspergillus disease, these 
cond itions are  p re sen t p rim arily  in  those w ith cavities, such 
as aspergillom a, and  indeed  num erous resistance m echanism s 
have b een  described  in  isolates ob ta in ed  from  this p a tie n t 
g ro u p  [25-27]. A m ong those, changes a t codon  220 have been  
identified , w hich w ere also fo u n d  in isolates in  o u r  study. 
H owever, isolates th a t develop azole resistance d u rin g  p a tie n t 
therapy  are  unlikely to cause fu r th e r  transm ission.
P e rson -to -person  transm ission  in  aspergillus disease is very 
uncom m on, re p o r te d  only th ro u g h  d irec t d o n o r- to -rec ip ien t 
co n tac t [30] an d  th ro u g h  in fec ted  w ounds [31]. G enerally, a 
p a tie n t who responds to  th erap y  overcom es the in fec tion  and  
tran sm ission  o f  th e  in fec tin g  iso late  is p rev en ted . T he 
alternative  ou tcom e is th a t a p a tie n t fails to  re sp o n d  to 
therapy , w hich com m only results in  death . T ransm ission  o f
any isolate a fte r  d ea th  appears to  be unlikely. A cquisition  of 
azole resistance in  patien ts , th e re fo re , is charac te rized  by a 
h igh variety  o f resistance m echanism s and  lack o f spread.
H owever, th e  p a tte rn  th a t we observed in the  co llection  of 
isolates from  o u r hosp ita l was qu ite  d ifferen t, w ith the 
dom inance  o f th e  TR/L98H resistance m echanism  in clinical 
isolates from  epidem iologically  u n re la ted  patien ts. F u r th e r­
m ore, m icrosatellite  typ ing  show ed th a t th e  genetic  distances 
betw een  the TR/L98H isolates was sh o rte r  th an  fo r o th e r 
azole-susceptible an d  azo le-resistan t isolates. These observa­
tions suggest th a t the TR/L98H isolate is n o t tran sm itted  from  
perso n  to  person , b u t m ight be p resen t in  o u r  env ironm ent. 
T he presence  o f Aspergillus species in th e  en v iro n m en t is 
co n sid ered  th e  m ost im p o rta n t risk fa c to r fo r  invasive 
aspergillosis, and  if  TR/L98H is p resen t in  o u r en v ironm en t 
res is tan t con id ia  will be d ispersed  in to  th e  am b ien t a ir and  
may cause in fec tion  th ro u g h  inhala tion . A. fumigatus resistan t 
to m edical azoles has been  recovered  from  the env ironm ent, 
ind ica ting  th a t this m ode o f transm ission  is feasible [32]. 
F u rth e rm o re , azo le-resistan t aspergillosis due to  TR/L98H 
was observed in  azole-na'ive patien ts , w hich suppo rts an 
env ironm en ta l o rig in  [5].
I t  rem ains un c lea r how  azole resistance develops in  A. 
fumigatus in  th e  env ironm ent. We hypothesize th a t resistance 
in A. fumigatus could  be caused by the use o f azole fungicides. 
Fungicides, inc lud ing  triazoles, a re  widely used  fo r b o th  p lan t 
p ro tec tio n  and  m ateria l p ro tec tio n  [33]. As A. fumigatus is a 
sap rophy tic  m ould, env ironm en ta l azole exposure could  lead  
to the  d ev e lo p m en t o f  m u ltip le  re s is tan t m utan ts . T he 
dom inance  o f th e  TR/L98H su bstitu tion  is difficult to  explain, 
b u t could  be due to  the p ro ced u re  we used  to select azole- 
res is tan t isolates, to  selective pressures in  the env ironm en t, o r
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to  p ro p e rtie s  o f these isolates th a t allow b e tte r  survival and  
sp read  in  th e  en v iro n m en t th an  isolates w ith  o th e r  m utations.
We believe th a t th e  d is trib u tio n  o f resistance m echanism s 
w ith in  the sets o f isolates th a t we investigated, reflects these 
two m odes o f resistance developm en t (p a tien t versus en v iron ­
m ent). V ariab le  resistance m echanism s w ere d o m in an t in  the 
re s is tan t iso lates fro m  o th e r  co u n tr ie s , c o n sis ten t w ith 
developm ent o f resistance in  individual azo le -trea ted  p a ­
tients. T he TR/L98H su bstitu tion  was th e  d o m in an t change in  
the isolates cu ltu red  from  o u r hosp ita l, w hich inc luded  all A. 
fumigatus isolates recovered  from  clinical specim ens irre sp ec ­
tive o f clinical significance, reflecting  acquisition  from  the 
env ironm ent. T he isolates sen t to  us from  o th e r D utch  
h osp ita l w ere exclusively fro m  p a tien ts  w ith  aspergillus 
diseases an d  th e re fo re  reflect a m ix tu re  o f the two m odes 
o f resistance developm ent.
O u r study was lim ited  by th e  fac t th a t the isolates from  
o th e r coun tries w ere n o t collected  w ith the in ten tio n  to  study 
the epidem iology o f resistance. A n accu ra te  estim ate  o f the 
sp read  o f resistance th e re fo re  could  n o t be ob ta ined , w hich 
w ould  re q u ire  p ro sp ec tiv e  surveillance studies. A n o th e r 
lim iting  fac to r was th a t we w ere unab le  to reliably d e te rm in e  
clinical factors th a t m ight p red ispose  fo r azole res is tan t 
aspergillosis. This was beyond  the p rim ary  focus o f o u r study 
and  w ould req u ire  a p rospective, m u lti-cen tre  study.
G iven the recen t an d  rap id  em ergence o f th e  TR/L98H 
resistance m echanism  in A. fumigatus, we believe th a t fu r th e r  
studies a re  u rgen tly  w arran ted . T he reasons fo r developm ent 
o f resistance an d  th e ir  transm ission  should  be investigated  by 
sam pling  o f th e  en v iro n m en t and, if  resistance is found , 
establish ing  a link  w ith  azole exposure. In  add ition , in te rn a ­
tional surveillance studies are  req u ired  to  d e te rm in e  the 
prevalence and  sp read  o f TR/L98H in o th e r  countries. O u r 
study does ind ica te  th a t th e  TR/L98H su bstitu tion  has sp read  
to  o th e r coun tries as one isolate from  N orway possessed the 
TR/L98H substitu tion . In  add ition , TR/L98H isolates have 
been  re p o r te d  from  Spain  [6], Belgium  [34], F rance, an d  the 
U n ited  K ingdom . O ne possible scenario  m igh t be th a t TR/ 
L98H  isolates have arisen  from  a single source an d  are 
subsequently  sp read ing  in  th e  en v iro n m en t across countries, 
w hich m ight be th e  beg inn ing  o f th e  global sp read  in  o u r 
en v iro n m en t o f azole resistance in  A. fumigatus.
I t is im p o rta n t to  exp lo re  the clinical factors th a t m ight be 
associated w ith  the  acquisition  o f TR/L98H isolates and  
associated disease, and  to d e te rm in e  the d ru g  o f choice fo r 
tre a tm e n t o f p a tien ts  w ith azole-resistan t aspergillosis. O u r 
data  ind ica te  th a t th e  activity o f voriconazole and  posacona- 
zole is red u ced  against the IT Z -resistan t isolates com pared  
w ith the co n tro l isolates. W hile aw aiting  th e  results o f 
confirm ative in te rn a tio n a l surveillance studies, we believe 
th a t clinical m icrobiology labo ra to ries should  d e te rm in e  the 
activity o f azoles a t least in  those isolates th a t a re  cu ltu red  
from  patien ts th a t fail to  re sp o n d  to azole therapy.
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Editors' Sum m ary
Background. Aspergillosis is a group of lung diseases caused by 
infection with Aspergillus, a mold (fungus) that grows on decaying plant 
matter. Because Aspergillus is widespread in the environment, people 
often breathe in its spores. For most people, this is not a problem—their 
immune system rapidly kills the fungal spores. However, people with 
asthma or cystic fibrosis sometimes develop allergic bronchopulmonary 
aspergillosis, a condition in which the spores trigger an allergic reaction 
in the lungs that causes coughing, wheezing. and breathlessness. Other 
people can develop an aspergilloma—a fungus ball that grows in 
cavities in the lung caused by other illnesses such as tuberculosis. 
However, the most serious form of aspergillosis is invasive aspergillosis. 
This pneumonia-like infection, which is fatal if left untreated, affects 
people who have a weakened immune system (for example, people with 
leukemia) and can spread from the lungs into the heart, brain, and other 
parts of the body. Aspergillosis is usually treated with triazole drugs, 
which inhibit an enzyme that the fungus needs to make its cell 
membranes; this enzyme is encoded by a gene called cyp51A. 
Voriconazole is the first-line therapy for aspergillosis but itraconazole 
and posaconazole are also sometimes used and ravuconazole is in 
clinical development.
Why Was This Study Done? About half of patients with invasive 
aspergillosis recover if they are given triazoles. Worryingly, however, 
strains of Aspergillus fumigatus (the type of Aspergillus usually involved in 
invasive aspergillosis) with resistance to several triazoles have recently 
been isolated from some patients in The Netherlands. If multi-azole 
resistant strains of A. fumigatus become common, they could have a 
serious impact on the management of invasive aspergillosis. However, 
noone knows what proportion of A. fumigatus strains isolated from 
patients with aspergillosis are resistant to several azole drugs. That is, 
noone knows the ‘‘prevalence’’ of multi-azole resistance. In this study, 
the researchers investigate the prevalence and development of azole 
resistance in A. fumigatus.
What Did the Researchers Do and Find? Since 1994, all fungal isolates 
from patients at the Radboud University Nijmegen Medical Center in the 
Netherlands have been stored. The researchers' search of this collection 
yielded 1,908 A. fumigatus isolates that had been collected from 1,219 
patients over a 14-year period. Of these, the isolates from 32 patients 
grew in the presence of itraconazole. All the itraconazole-resistant
isolates (which also had increased resistance to voriconazole, ravucona- 
zole, and posaconazole) were collected after 1999; the annual prevalence 
of itraconazole-resistant isolates ranged from 1.7% to 6%. The 
researchers then sequenced the cyp51A gene in each resistant isolate. 
Thirty had a genetic alteration represented as TR/L98H. This ‘‘dominant 
resistance mechanism’’ consisted of a single amino acid change in the 
cyp51A gene and an alteration in the gene's promoter region (the region 
that controls how much protein is made from a gene). The researchers 
also analyzed A. fumigatus isolates from patients admitted to 28 other 
hospitals in the Netherlands. Itraconazole resistance was present in 
isolates from 13 patients (out of 101 patients) from nine hospitals; the 
TR/L98H genetic alteration was present in 69% of the itraconazole- 
resistant isolates. Finally, itraconazole resistance was present in six 
isolates from four other countries (out of 317 isolates from six countries); 
only one Norwegian isolate had the TR/L98H genetic alteration.
What Do These Findings Mean? These findings indicate that azole 
resistance is emerging in A. fumigatus and may already be more 
prevalent than generally thought. Given the dominance of the TR/L98H 
genetic alteration in the azole-resistant clinical isolates, the researchers 
suggest that A. fumigatus isolates harboring this alteration might be 
present and spreading in the environment rather than being selected for 
during azole treatment of patients. Why azole resistance should develop 
in A. fumigatus in the environment is unclear but might be caused by the 
use of azole-containing fungicides. Further studies are now urgently 
needed to find out if this is the case, to measure the international 
prevalence and spread of A. fumigatus isolates harboring the TR/L98H 
genetic alteration, and, most importantly, to develop alternative treat­
ments for patients with azole-resistant aspergillosis.
Additional Information. Please access these Web sites via the online 
version of this summary at http://dx.doi.org/10.1371/journal.pmed. 
0050219.
• The MedlinePlus Medical Encyclopedia has a page on aspergillosis (in 
English and Spanish)
• The UK National Health Service Direct health encyclopedia has 
detailed information about all aspects of aspergillosis
• The US Centers for Disease Control and Prevention also has 
information about aspergillosis
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